You have no items in your cart.
EDG-5506 Safely Lowering Muscle Damage Markers in Becker MD Trial
Muscular Dystrophy News
The experimental oral therapy EDG-5506 has been generally well-tolerated and lowered markers of muscle damage among men with Becker muscular dystrophy (BMD) in the open-label ARCH clinical trial, early data show. ... Read more